More about GLP-1 medicine – Rybelsus

Index

1. What is Rybelsus?
2. Precautions needed when using Rybelsus

1. What is Rybelsus?

Rybelsus is an orally administered drug developed by Novo Nordisk for effective weight control. Rybelsus works similarly to Saxenda as a GLP-1 agonist.

Rybelsus is the world`s first and only GLP-1 agonist approved for weight control treatment and treatment of type 2 diabetes. The medicine is used to improve glycemic control in patients with inadequate response to diet and exercise therapy. Unlike Saxenda, which is an injection-administered drug, Rybelsus comes in tablets that are easy to take. Like Saxenda, the drug is more effective when taken while dieting and exercising. Rybelsus is approved by the FDA in the U.S. and Japan.

2.Precautions needed when using Rybelsus

Although it varies from person to person, the following side effects may occur: • Gastrointestinal symptoms (constipation, diarrhea, nausea, gastric discomfort, dehydration) • Hypoglycemic symptoms (weakness, fatigue, severe hunger, cold sweats, pallor, palpitations, tremors, headache, dizziness, nausea, visual abnormalities, etc.) • Acute pancreatitis • Intestinal obstruction • Medullary thyroid cancer • Depression If you experience any serious side effects, please consult with your doctor and/or clinic.

Do not use Rybelsus if you have any of the followings: • If you have a medical condition or if you are under treatment • If you are allergic to Liraglutide or any of the ingredients in GLP-1 • If you are pregnant, expecting a baby, breastfeeding, or within 3 months of postpartum

Please consult with our doctor if you have any of the above.